Evidence map›Paper›PMID 22114137›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012

Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.

Brooke E Sylvester, Dezheng Huo, Andrey Khramtsov, Jing Zhang, Rana V Smalling, Sope Olugbile, Blase N Polite, Olufunmilayo I Olopade

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Novel recurrently mutated genes in African American colon cancers.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Trial
  4. Trial
  5. Article
  6. International journal of molecular sciences · 2023
    Article
  7. Article
  8. Molecular genetics of early-onset colorectal cancer.World journal of biological chemistry · 2023
    Review
  9. Predictors of Incident Serrated Polyps: Results from a Large Multicenter Clinical Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Clinicopathological Significance ofJournal of Cancer · 2019
    Article
  14. Not all mutations ofInternational journal of clinical and experimental pathology · 2019
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brooke E SylvesterCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Dezheng Huo
Andrey Khramtsov
Jing Zhang
Rana V Smalling
Sope Olugbile
Blase N Polite
Olufunmilayo I Olopade
University of Chicago · USCancer Genetics (United States) · US

Funding

Variation in Hormone and xenobiotic metabolizing enzyme genes and breast cancerP50CA125183 · NCI · UNIVERSITY OF CHICAGO · PI OLOPADE, OLUFUNMILAYO F. · 2006 to 2010
$11.3M
BASIC RESEARCH TRAINING IN MEDICAL ONCOLOGYT32CA009566 · NCI · UNIVERSITY OF CHICAGO · PI OLUFUNMILAYO F. OLOPADE · 1987 to 2026
$10.5M
Molecular Genetics of Colorectal Cancer Progression in a Diverse Patient CohortF31CA136237 · NCI · UNIVERSITY OF CHICAGO · PI SYLVESTER, BROOKE E · 2008 to 2011
$77k
NCI NIH HHS 5P50CA125183-04NCI NIH HHS F31 CA136237NCI NIH HHS F31CA136237NCI NIH HHS P50 CA125183NCI NIH HHS T32 CA009566
6 · The paper itself

Abstract

purposeAfrican American colorectal cancer patients have worse survival outcomes than Caucasian patients. To determine whether differences exist in the molecular mechanisms driving colorectal cancer between African Americans and Caucasians, we characterized patient tumors from a single institution by assessing genetic alterations involved in colorectal cancer progression and response to treatment. EXPERIMENTAL

designWe retrospectively examined 448 African Americans and Caucasians diagnosed with colorectal cancer at The University of Chicago Medical Center between 1992 and 2002. Microsatellite instability (MSI) status was determined by genotyping the BAT25, BAT26, BAT40, D5S346, and BAX loci. Mutations in KRAS codons 12 and 13 and BRAF codon 600 were identified by direct sequencing. MSI and detected mutations were correlated with clinicopathologic features.

resultsOverall, no difference existed in MSI or BRAF mutation frequencies between African Americans and Caucasians. However, African Americans with microsatellite stable (MSS)/MSI-low (MSI-L) tumors had a higher proportion of KRAS mutations than Caucasians (34% vs. 23%, P = 0.048) that was isolated to proximal colon cancers and primarily driven by mutations in codon 13. There was no racial difference in receipt of chemotherapy, but African Americans with MSS/MSI-L tumors had a 73% increased risk of death over Caucasians that could not be explained by known prognostic factors.

conclusionsThe significantly higher risk of death among African Americans with MSS/MSI-L tumors may be related to differences in the distribution of factors influencing response to standard therapies. These data underscore the need for further research into the molecular mechanisms driving colorectal cancer progression in underserved and understudied populations.

Indexed as

AgedAged, 80 and overBlack or African AmericanCohort StudiesColorectal NeoplasmsDNA Mutational AnalysisFemaleHumansKaplan-Meier EstimateMaleMicrosatellite InstabilityMiddle AgedMultivariate AnalysisPrognosisProportional Hazards ModelsProto-Oncogene ProteinsBRAF protein, humanKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID22114137
PMCPMC3272273
OpenAlexW2098760883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.